{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:05:33Z","timestamp":1794333933908,"version":"4.9.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The study aimed to evaluate risk factors for macular atrophy (MA) associated with myopic choroidal neovascularization (mCNV) during long-term follow-up after intravitreal anti-vascular endothelial growth factor (VEGF) treatment in highly myopic eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of patients who received intravitreal injection of anti-VEGF agents as mCNV treatment and were followed-up for more than 36 months were retrospectively reviewed. The risk factors for the development of mCNV-MA, which is the fovea-involving patchy atrophy lesion adjacent to mCNV, were investigated using the Cox proportional hazard model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 82 eyes (74 patients) were included in the study. The mean age at anti-VEGF treatment was 56.3 \u00b1 12.5 years (range, 26\u201377), and the mean follow-up period was 76.3 \u00b1 33.5 months (range, 36\u2013154). During follow-up, mCNV-MA developed in 27 eyes (32.9%), and its occurrence was estimated to be 24.5% at 3 years and 37.3% at 5 years after the first anti-VEGF treatment. Old age (hazard ratio [HR] = 1.054, 95% confidence interval [CI]: 1.018\u20131.091;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003) and greater CNV size at baseline (HR = 2.396, CI: 1.043\u20135.504;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.040) were significant factors for mCNV-MA development. Eyes with a thinner subfoveal choroid were more likely to show faster enlargement of the mCNV-MA during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In mCNV eyes treated with intravitreal anti-VEGF agents, older age and greater mCNV size at baseline were risk factors for the development of MA during long-term follow-up, which was associated with a poor visual prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0273613","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T13:58:03Z","timestamp":1663855083000},"page":"e0273613","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-2826","authenticated-orcid":true,"given":"Ki Woong","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-4808","authenticated-orcid":true,"given":"Bo Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Lok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-1235","authenticated-orcid":true,"given":"Eun Kyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ki","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-4497","authenticated-orcid":true,"given":"Un Chul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"3","key":"pone.0273613.ref001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","article-title":"Myopic choroidal neovascularisation: current concepts and update on clinical management","volume":"99","author":"TY Wong","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"pone.0273613.ref002","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"K Hayashi","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0273613.ref003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ophtha.2006.05.071","article-title":"Characteristics of highly myopic eyes: the Beijing Eye Study","volume":"114","author":"L Xu","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0273613.ref004","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0161-6420(01)01024-7","article-title":"Prevalence and progression of myopic retinopathy in an older population","volume":"109","author":"J Vongphanit","year":"2002","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0273613.ref005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","article-title":"Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes","volume":"254","author":"V Sarao","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"pone.0273613.ref006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"TY Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0273613.ref007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study","volume":"122","author":"Y Ikuno","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0273613.ref008","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"S Wolf","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"pone.0273613.ref009","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"A Tufail","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0273613.ref010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357290","article-title":"Progression of myopic maculopathy after treatment of choroidal neovascularization","volume":"231","author":"CL Farinha","year":"2014","journal-title":"Ophthalmologica"},{"issue":"1","key":"pone.0273613.ref011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10384-014-0363-z","article-title":"Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab","volume":"59","author":"SY Cohen","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"pone.0273613.ref012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajo.2015.11.014","article-title":"Macular Bruch Membrane Holes in Choroidal Neovascularization-Related Myopic Macular Atrophy by Swept-Source Optical Coherence Tomography","volume":"162","author":"K Ohno-Matsui","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"pone.0273613.ref013","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"K Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"pone.0273613.ref014","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.ophtha.2014.03.035","article-title":"Proposed classification of posterior staphylomas based on analyses of eye shape by three-dimensional magnetic resonance imaging and wide-field fundus imaging","volume":"121","author":"K. Ohno-Matsui","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0273613.ref015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ajo.2012.08.007","article-title":"Three-dimensional tomographic features of dome-shaped macula by swept-source optical coherence tomography","volume":"155","author":"AA Ellabban","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0273613.ref016","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archopht.122.10.1455","article-title":"Optical coherence tomography findings in myopic traction maculopathy","volume":"122","author":"G Panozzo","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"pone.0273613.ref017","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ajo.2013.06.031","article-title":"Natural course of myopic traction maculopathy and factors associated with progression or resolution","volume":"156","author":"N Shimada","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"pone.0273613.ref018","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1097\/IAE.0000000000001043","article-title":"Subretinal Fibrosis after Antivascular Endothelial Growth Factor Therapy in Eyes with Myopic Choroidal Neovascularization","volume":"36","author":"SJ Ahn","year":"2016","journal-title":"Retina"},{"issue":"7","key":"pone.0273613.ref019","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"T Yoshida","year":"2003","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0273613.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-012-2022-8","article-title":"Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization","volume":"251","author":"A Oishi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"pone.0273613.ref021","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"K Hayashi","year":"2012","journal-title":"Retina"},{"issue":"7","key":"pone.0273613.ref022","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00417-011-1921-4","article-title":"Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"250","author":"R Uemoto","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"pone.0273613.ref023","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/IAE.0000000000001384","article-title":"Choroidal Thickness and Chorioretinal Atrophy in Myopic Choroidal Neovascularization with Anti-Vascular Endothelial Growth Factor Therapy","volume":"37","author":"JH Lee","year":"2017","journal-title":"Retina"},{"issue":"12","key":"pone.0273613.ref024","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Secondary to Pathologic Myopia: Six Years Outcome","volume":"35","author":"JM Ruiz-Moreno","year":"2015","journal-title":"Retina"},{"issue":"1","key":"pone.0273613.ref025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results","volume":"147","author":"Y Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0273613.ref026","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1167\/iovs.12-11352","article-title":"Macular Bruch\u2019s membrane defects and axial length: association with gamma zone and delta zone in peripapillary region","volume":"54","author":"JB Jonas","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"pone.0273613.ref027","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00417-003-0803-9","article-title":"Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia","volume":"242","author":"A Kojima","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"pone.0273613.ref028","first-page":"1068","article-title":"Absorption of retinal and subretinal hemorrhages","volume":"15","author":"A Gillies","year":"1983","journal-title":"Ann Ophthalmol."},{"issue":"7","key":"pone.0273613.ref029","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1167\/iovs.09-3493","article-title":"Ocular risk factors for choroidal neovascularization in pathologic myopia","volume":"51","author":"Y Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0273613.ref030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12886-015-0059-2","article-title":"Choroidal thickness and high myopia: a cross-sectional study and meta-analysis","volume":"15","author":"S Wang","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"pone.0273613.ref031","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1167\/iovs.14-16006","article-title":"Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization","volume":"56","author":"SJ Ahn","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"pone.0273613.ref032","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ophtha.2019.01.012","article-title":"OCT-Based Diagnostic Criteria for Different Stages of Myopic Maculopathy","volume":"126","author":"Y Fang","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0273613.ref033","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1167\/iovs.12-11542","article-title":"Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization","volume":"54","author":"SJ Ahn","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"pone.0273613.ref034","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":"Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization","volume":"26","author":"TY Lai","year":"2012","journal-title":"Eye (Lond)."},{"issue":"8","key":"pone.0273613.ref035","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","article-title":"Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"32","author":"P Iacono","year":"2012","journal-title":"Retina"},{"key":"pone.0273613.ref036","first-page":"8639243","article-title":"Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results-A Retrospective, Comparative Study","volume":"2019","author":"B Erden","year":"2019","journal-title":"Comparison ofJ Ophthalmol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T13:59:04Z","timestamp":1663855144000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273613"}},"subtitle":[],"editor":[{"given":"Alfred S.","family":"Lewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273613","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0273613.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0273613.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0273613.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0273613.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0273613.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0273613.s001","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}